Health information technology interventions and engagement in HIV care and achievement of viral suppression in publicly funded settings in the US: A cost-effectiveness analysis.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
18
08
2019
accepted:
25
03
2021
revised:
21
04
2021
pubmed:
8
4
2021
medline:
5
8
2021
entrez:
7
4
2021
Statut:
epublish
Résumé
The US National HIV/AIDS Strategy (NHAS) emphasizes the use of technology to facilitate coordination of comprehensive care for people with HIV. We examined cost-effectiveness from the health system perspective of 6 health information technology (HIT) interventions implemented during 2008 to 2012 in a Ryan White HIV/AIDS Program (RWHAP) Special Projects of National Significance (SPNS) Program demonstration project. HIT interventions were implemented at 6 sites: Bronx, New York; Durham, North Carolina; Long Beach, California; New Orleans, Louisiana; New York, New York (2 sites); and Paterson, New Jersey. These interventions included: (1) use of HIV surveillance data to identify out-of-care individuals; (2) extension of access to electronic health records (EHRs) to support service providers; (3) use of electronic laboratory ordering and prescribing; and (4) development of a patient portal. We employed standard microcosting techniques to estimate costs (in 2018 US dollars) associated with intervention implementation. Data from a sample of electronic patient records from each demonstration site were analyzed to compare prescription of antiretroviral therapy (ART), CD4 cell counts, and suppression of viral load, before and after implementation of interventions. Markov models were used to estimate additional healthcare costs and quality-adjusted life-years saved as a result of each intervention. Overall, demonstration site interventions cost $3,913,313 (range = $287,682 to $998,201) among 3,110 individuals (range = 258 to 1,181) over 3 years. Changes in the proportion of patients prescribed ART ranged from a decrease from 87.0% to 72.7% at Site 4 to an increase from 74.6% to 94.2% at Site 6; changes in the proportion of patients with 0 to 200 CD4 cells/mm3 ranged from a decrease from 20.2% to 11.0% in Site 6 to an increase from 16.7% to 30.2% in Site 2; and changes in the proportion of patients with undetectable viral load ranged from a decrease from 84.6% to 46.0% in Site 1 to an increase from 67.0% to 69.9% in Site 5. Four of the 6 interventions-including use of HIV surveillance data to identify out-of-care individuals, use of electronic laboratory ordering and prescribing, and development of a patient portal-were not only cost-effective but also cost saving ($6.87 to $14.91 saved per dollar invested). In contrast, the 2 interventions that extended access to EHRs to support service providers were not effective and, therefore, not cost-effective. Most interventions remained either cost-saving or not cost-effective under all sensitivity analysis scenarios. The intervention that used HIV surveillance data to identify out-of-care individuals was no longer cost-saving when the effect of HIV on an individual's health status was reduced and when the natural progression of HIV was increased. The results of this study are limited in that we did not have contemporaneous controls for each intervention; thus, we are only able to assess sites against themselves at baseline and not against standard of care during the same time period. These results provide additional support for the use of HIT as a tool to enhance rapid and effective treatment of HIV to achieve sustained viral suppression. HIT has the potential to increase utilization of services, improve health outcomes, and reduce subsequent transmission of HIV.
Sections du résumé
BACKGROUND
The US National HIV/AIDS Strategy (NHAS) emphasizes the use of technology to facilitate coordination of comprehensive care for people with HIV. We examined cost-effectiveness from the health system perspective of 6 health information technology (HIT) interventions implemented during 2008 to 2012 in a Ryan White HIV/AIDS Program (RWHAP) Special Projects of National Significance (SPNS) Program demonstration project.
METHODS/FINDINGS
HIT interventions were implemented at 6 sites: Bronx, New York; Durham, North Carolina; Long Beach, California; New Orleans, Louisiana; New York, New York (2 sites); and Paterson, New Jersey. These interventions included: (1) use of HIV surveillance data to identify out-of-care individuals; (2) extension of access to electronic health records (EHRs) to support service providers; (3) use of electronic laboratory ordering and prescribing; and (4) development of a patient portal. We employed standard microcosting techniques to estimate costs (in 2018 US dollars) associated with intervention implementation. Data from a sample of electronic patient records from each demonstration site were analyzed to compare prescription of antiretroviral therapy (ART), CD4 cell counts, and suppression of viral load, before and after implementation of interventions. Markov models were used to estimate additional healthcare costs and quality-adjusted life-years saved as a result of each intervention. Overall, demonstration site interventions cost $3,913,313 (range = $287,682 to $998,201) among 3,110 individuals (range = 258 to 1,181) over 3 years. Changes in the proportion of patients prescribed ART ranged from a decrease from 87.0% to 72.7% at Site 4 to an increase from 74.6% to 94.2% at Site 6; changes in the proportion of patients with 0 to 200 CD4 cells/mm3 ranged from a decrease from 20.2% to 11.0% in Site 6 to an increase from 16.7% to 30.2% in Site 2; and changes in the proportion of patients with undetectable viral load ranged from a decrease from 84.6% to 46.0% in Site 1 to an increase from 67.0% to 69.9% in Site 5. Four of the 6 interventions-including use of HIV surveillance data to identify out-of-care individuals, use of electronic laboratory ordering and prescribing, and development of a patient portal-were not only cost-effective but also cost saving ($6.87 to $14.91 saved per dollar invested). In contrast, the 2 interventions that extended access to EHRs to support service providers were not effective and, therefore, not cost-effective. Most interventions remained either cost-saving or not cost-effective under all sensitivity analysis scenarios. The intervention that used HIV surveillance data to identify out-of-care individuals was no longer cost-saving when the effect of HIV on an individual's health status was reduced and when the natural progression of HIV was increased. The results of this study are limited in that we did not have contemporaneous controls for each intervention; thus, we are only able to assess sites against themselves at baseline and not against standard of care during the same time period.
CONCLUSIONS
These results provide additional support for the use of HIT as a tool to enhance rapid and effective treatment of HIV to achieve sustained viral suppression. HIT has the potential to increase utilization of services, improve health outcomes, and reduce subsequent transmission of HIV.
Identifiants
pubmed: 33826617
doi: 10.1371/journal.pmed.1003389
pii: PMEDICINE-D-19-02957
pmc: PMC8059802
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003389Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Health Aff (Millwood). 2007 Jan-Feb;26(1):206-14
pubmed: 17211030
J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):100-8
pubmed: 19295340
J Acquir Immune Defic Syndr. 1999 Aug 1;21(4):293-300
pubmed: 10428107
Health Aff (Millwood). 2005 Sep-Oct;24(5):1127-37
pubmed: 16162555
Antivir Ther. 2006;11(3):305-14
pubmed: 16759046
Med Care. 1999 Dec;37(12):1270-81
pubmed: 10599608
Arch Pediatr Adolesc Med. 2001 Sep;155(9):1002-7
pubmed: 11529801
Med Care. 2006 Nov;44(11):990-7
pubmed: 17063130
Clin Infect Dis. 2011 Jan 15;52 Suppl 2:S238-46
pubmed: 21342913
J Public Health Manag Pract. 2010 Nov-Dec;16(6):521-8
pubmed: 20885182
PLoS One. 2010 Jun 10;5(6):e11068
pubmed: 20548786
Arch Intern Med. 2008 Jun 9;168(11):1181-7
pubmed: 18541826
BMC Med Inform Decis Mak. 2011 Dec 30;11:78
pubmed: 22208182
Int J Med Inform. 2012 Oct;81(10):e1-9
pubmed: 22854158
J Health Care Poor Underserved. 1999 Feb;10(1):45-71
pubmed: 9989006
N Engl J Med. 2001 Mar 15;344(11):817-23
pubmed: 11248159
JMIR Med Inform. 2015 Dec 15;3(4):e39
pubmed: 26678413
Ann Intern Med. 2010 Dec 21;153(12):778-89
pubmed: 21173412
J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):451-7
pubmed: 16980906
N Engl J Med. 2005 Feb 10;352(6):586-95
pubmed: 15703423
AIDS Care. 2002 Aug;14 Suppl 1:S7-14
pubmed: 12204138
AIDS Res Hum Retroviruses. 2011 Jul;27(7):751-8
pubmed: 21142607
HIV Clin Trials. 2009 Jul-Aug;10(4):233-53
pubmed: 19723611
Health Aff (Millwood). 2009 Mar-Apr;28(2):w282-93
pubmed: 19174390
Ann Intern Med. 2014 Dec 2;161(11):803-11
pubmed: 25437408
AIDS Patient Care STDS. 2004 Dec;18(12):714-20
pubmed: 15659882
Am J Manag Care. 2014 May;20(5):e129-37
pubmed: 25326927
Arch Intern Med. 2007 Apr 23;167(8):788-94
pubmed: 17452541
PLoS Med. 2017 May 24;14(5):e1002312
pubmed: 28542184
AIDS Patient Care STDS. 2007;21 Suppl 1:S3-8
pubmed: 17563287
Pediatrics. 2009 Jan;123 Suppl 2:S67-73
pubmed: 19088232
J Gen Intern Med. 2000 Dec;15(12):833-40
pubmed: 11119179
PLoS One. 2007 Jan 24;2(1):e173
pubmed: 17245449
Top HIV Med. 2008 Dec;16(5):156-61
pubmed: 19106431
N Engl J Med. 2005 Feb 10;352(6):570-85
pubmed: 15703422
J Am Med Inform Assoc. 1994 Sep-Oct;1(5):361-71
pubmed: 7850560
N Engl J Med. 1998 Dec 24;339(26):1897-904
pubmed: 9862946
AIDS Care. 2011 Nov;23(11):1366-73
pubmed: 22022847
J Biomed Inform. 2007 Dec;40(6 Suppl):S40-5
pubmed: 17950041
AIDS Care. 2004;16 Suppl 1:S22-42
pubmed: 15736820
J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):213-8
pubmed: 15671808
Int J Med Inform. 1999 Feb-Mar;53(2-3):133-42
pubmed: 10193883
Health Aff (Millwood). 2015 Mar;34(3):477-83
pubmed: 25732499
AIDS Patient Care STDS. 2011 Feb;25(2):79-88
pubmed: 21284498
Antivir Ther. 2003 Oct;8(5):443-54
pubmed: 14640392
J Acquir Immune Defic Syndr. 2000 Dec 1;25(4):337-44
pubmed: 11114834
Int J Med Inform. 2012 Oct;81(10):e10-20
pubmed: 22841703
Health Aff (Millwood). 2017 Aug 1;36(8):1416-1422
pubmed: 28784734
Home Health Care Serv Q. 2001;19(1-2):53-75
pubmed: 11357465
Appl Clin Inform. 2011 Nov 30;2(4):499-507
pubmed: 23616891
Comput Methods Programs Biomed. 2018 Jul;161:209-232
pubmed: 29852963
J Am Med Inform Assoc. 2006 May-Jun;13(3):261-6
pubmed: 16501178
Med Care. 2005 Aug;43(8):834-9
pubmed: 16034298
Clin Infect Dis. 2009 Jan 15;48(2):248-56
pubmed: 19072715
Int J Med Inform. 2012 Oct;81(10):e21-9
pubmed: 22854159
AIDS Patient Care STDS. 2000 Jul;14(7):381-90
pubmed: 10935054
Clin Infect Dis. 2011 Mar 15;52(6):793-800
pubmed: 21367734